Earlier this year, Bill Gates caused a ripple in the media by expressing optimism that a vaccine and a cure for HIV will become a reality within the next 15 years. From TAG’s perspective, Gates’s buoyancy does have some scientific basis—there have been encouraging signs of progress on both the vaccine and cure fronts in recent years—but the challenges that lie ahead must not be underestimated.
13 April 2015 | Treatment Action Group
There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper published yesterday in Nature describes encouraging results from a phase I trial involving the bNAb 3BNC117. Reflecting the level of interest in the topic, the paper has attracted extensive press coverage.
10 April 2015 | TAG
The new study, conducted in Michel Nussenzweig’s Laboratory of Molecular Immunology, finds that administration of a potent antibody, called 3BNC117, can catch HIV off guard and reduce viral loads.
09 April 2015 | Rockefeller University press release
Wayne Koff, chief scientific officer at the International AIDS Vaccine Initiative (IAVI), spoke in an interview about the challenges in developing a vaccine for one of the trickiest and deadliest known viruses, how scientists are getting closer to developing a vaccine for human immunodeficiency virus (HIV), and what makes India attractive for vaccine development.
01 April 2015 | Hindustan Times
Immune Response BioPharma, Inc., Today provides an update on REMUNE and announces the FDA has accepted the REMUNE HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS.
31 March 2015 | Immune Response BioPharma press release
Researchers at the University of Rochester Medical Center are testing a new oral vaccine to prevent infection with HIV, the virus that causes AIDS. The vaccine is unique because it is given as a pill, unlike most HIV vaccines tested to date that have been given as shots.
20 February 2015 | University of Rochester press release
A clinical trial has launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in volunteers. This experimental regimen is based on the one tested in the RV144 trial - -the first to demonstrate that a vaccine can protect people from HIV infection -- but is designed to potentially provide greater protection and is adapted to the predominant HIV subtype in southern Africa.
19 February 2015 | Eurekalert Medicine & Health
For more than three decades, scientists have tried unsuccessfully to develop an effective vaccine for HIV, the virus that causes AIDS. But now researchers say they have created an experimental drug that may function as a sort of "alternative" vaccine for the virus. The experimental drug, a protein known as eCD4-IG, blocks infection by keeping the virus from binding to the immune cells that are the virus's target. In tests on monkeys, the drug "candidate" proved to be extremely effective at blocking infection--even with the most virulent strains of HIV and its simian counterpart, SIV.
19 February 2015 | Huffington Post
Researchers Carefully Tailor a Study to Find Patients to Test Going Off Antiretroviral Medication
16 February 2015 | Wall Street Journal
A few days ago while in Abuja, I was surprised to hear the news presenter announce that a Federal High Court had “lifted the ban” on Dr Abalaka’s “vaccine” against HIV. I was struck by a number of things – an abiding discomfort at the quality of reporting on science and health matters in the Nigerian media; a sense of guilt that, in failing to tell our stories, younger Nigerians are at risk of repeating missteps of the past; and a fear that many, misled by the news item, may put their lives at risk.
28 January 2015 | Nigeria Health Watch